Sterilized Product Processing and Cutting-Edge Production Line
Bold Investment Turning the 'Post-Corona Era' Crisis into Opportunity
[Asia Economy Reporter Hyungsoo Park] Spinal implant company L&K Biomed is set to fully commence production of sterile spinal implants using a sterilized product process.
On the 12th at 10 a.m., L&K Biomed held a completion ceremony for its second factory at its headquarters located in Yongin, Gyeonggi Province. The second factory was designed to allow equipment centralization for each process. Cutting-edge facilities such as production CNC machines, development equipment MCT, reliability verification MCT, and temperature and humidity-controlled chambers were established to increase production capacity. In preparation for increased overseas exports, including to the U.S. market, the existing production volume will be doubled.
At the completion ceremony, Park Geun-joo, CEO of L&K Biomed, said, "Last year, when we announced the construction of the second factory amid the growing uncertainty of the global economy due to the COVID-19 pandemic, there were considerable concerns."
He continued, "As the U.S., our main market, has emerged from the pandemic tunnel thanks to vaccine supply, demand for spinal implants is increasing. As the saying goes, 'crisis is opportunity,' and the bold decision made during difficult times has allowed us to dream of a greater future."
CEO Park also stated, "The second factory will serve as a key asset for L&K Biomed and a production outpost for the height-expandable interbody fusion cage, a future growth engine prepared for the 'post-COVID' era," adding, "It holds significant meaning as the starting point of the big picture the company has envisioned."
The second factory has established dedicated production lines for each product to enhance production efficiency, and aims to shorten product development lead times and improve customer satisfaction through dedicated R&D lines. In addition to increasing basic production capacity due to expansion, the introduction of new equipment such as MCT and CNC composite machines for efficient manufacturing of precision parts is expected to improve product quality.
The second factory will include specialized production facilities for the flagship product, the height-expandable interbody fusion cage, as well as a showroom for product promotion.
Son Woo-geun, Head of Production Technology Division and Factory Manager, said, "The second factory can increase production volume while reducing manufacturing costs through optimized processes," adding, "We are introducing specialized production facilities for research and customer response." He further stated, "We can quickly respond to diverse customer needs, which will enhance customer loyalty and secure a competitive advantage over rivals."
L&K Biomed has upgraded its production lines to sterilization systems suitable for ‘untact’ (non-face-to-face) services following the COVID-19 pandemic. The entire product lineup in the second factory has been sterilized, and the process has been expanded to enable sterile production of surgical instruments as well. It is expected to serve as a spinal implant production base prepared for the ‘post-COVID’ era.
A company official said, "L&K Biomed is one of the world’s leading companies with technology that succeeded in developing the expandable cage, which even top global spinal implant companies repeatedly failed to develop," and expressed confidence, "With the completion of the second factory, we announce the emergence of a new powerhouse in the spinal implant industry and expect to achieve a quantum jump in performance."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
